Literature DB >> 16421140

Heterogeneity of Parkinson's disease.

A Schrag, N P Quinn, Y Ben-Shlomo.   

Abstract

Entities:  

Mesh：

Year:  2006        PMID： 16421140      PMCID： PMC2077583          DOI： 10.1136/jnnp.2005.074393

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  2 in total

1.  Cross sectional prevalence survey of idiopathic Parkinson's disease and Parkinsonism in London.

Authors:  A Schrag; Y Ben-Shlomo; N P Quinn
Journal:  BMJ       Date:  2000-07-01

2.  Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach.

Authors:  S J G Lewis; T Foltynie; A D Blackwell; T W Robbins; A M Owen; R A Barker
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-03       Impact factor: 10.154
  2 in total
  15 in total

1.  Nanomedicine in the diagnosis and therapy of neurodegenerative disorders.

Authors:  A V Kabanov; H E Gendelman
Journal:  Prog Polym Sci       Date:  2007       Impact factor: 29.190

2.  Clinical heterogeneity in newly diagnosed Parkinson's disease.

Authors:  Bart Post; Johannes D Speelman; Rob J de Haan
Journal:  J Neurol       Date:  2008-03-17       Impact factor: 4.849

Review 3.  Neural networks engaged in milliseconds and seconds time processing: evidence from transcranial magnetic stimulation and patients with cortical or subcortical dysfunction.

Authors:  Giacomo Koch; Massimiliano Oliveri; Carlo Caltagirone
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2009-07-12       Impact factor: 6.237

4.  Familial aggregation of panic disturbances in Parkinson's disease.

Authors:  Gregory M Pontone; Justin Palanci; O Joseph Bienvenu; Kung-Yee Liang; Gerald Nestadt; Peter V Rabins; James R Williams; Laura Marsh
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2011       Impact factor: 2.198

5.  Interval timing and Parkinson's disease: heterogeneity in temporal performance.

Authors:  Hugo Merchant; Monica Luciana; Catalina Hooper; Stacy Majestic; Paul Tuite
Journal:  Exp Brain Res       Date:  2007-09-09       Impact factor: 1.972

Review 6.  Neurodegenerative disorders and nanoformulated drug development.

Authors:  Ari Nowacek; Lisa M Kosloski; Howard E Gendelman
Journal:  Nanomedicine (Lond)       Date:  2009-07       Impact factor: 5.307

Review 7.  Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases.

Authors:  David G Coughlin; Howard I Hurtig; David J Irwin
Journal:  Mov Disord       Date:  2019-10-29       Impact factor: 10.338

8.  Methodological considerations of evaluating the rate of presynaptic dopaminergic denervation in Parkinson disease with radiotracers: Analysis of the PPMI data.

Authors:  Jeong Won Lee; Yoo Sung Song; Hyeyun Kim; Bon D Ku; Won Woo Lee
Journal:  Medicine (Baltimore)       Date:  2021-07-02       Impact factor: 1.817

Review 9.  Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease.

Authors:  Daniela Berg; Ronald B Postuma; Bastiaan Bloem; Piu Chan; Bruno Dubois; Thomas Gasser; Christopher G Goetz; Glenda M Halliday; John Hardy; Anthony E Lang; Irene Litvan; Kenneth Marek; José Obeso; Wolfgang Oertel; C Warren Olanow; Werner Poewe; Matthew Stern; Günther Deuschl
Journal:  Mov Disord       Date:  2014-03-11       Impact factor: 10.338

10.  Identifying the clusters within nonmotor manifestations in early Parkinson's disease by using unsupervised cluster analysis.

Authors:  Hui-Jun Yang; Young Eun Kim; Ji Young Yun; Han-Joon Kim; Beom Seok Jeon
Journal:  PLoS One       Date:  2014-03-18       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.